Chemistry and DMPK, Oncology R&D, AstraZeneca, 1 Francis Crick Avenue, Cambridge CB2 0AA, United Kingdom.
Chemistry and DMPK, Research and Early Development, Respiratory and Immunology, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Pepparedsleden 1, Mölndal 43183, Sweden.
J Med Chem. 2024 Aug 8;67(15):13106-13116. doi: 10.1021/acs.jmedchem.4c01017. Epub 2024 Jul 30.
Achieving oral bioavailability with Proteolysis Targeting Chimeras (PROTACs) is a key challenge. Here, we report the pharmacokinetic properties in mouse, rat, and dog of four clinical oral PROTACs and compare with an internally derived data set. We use NMR to determine 3D molecular conformations and structural preorganization free in solution, and we introduce the new experimental descriptors, solvent-exposed H-bond donors (eHBD), and acceptors (eHBA). We derive an upper limit of eHBD ≤ 2 for oral PROTACs in apolar environments and show a greater tolerance for other properties (eHBA, polarity, lipophilicity, and molecular weight) than for Rule-of-5 compliant oral drugs. Within a set of structurally related PROTACs, we show that examples with eHBD > 2 have much lower oral bioavailability than those that have eHBD ≤ 2. We summarize our findings as an experimental "Rule-of-oral-PROTACs" in order to assist medicinal chemists to achieve oral bioavailability in this challenging space.
实现蛋白水解靶向嵌合体(PROTACs)的口服生物利用度是一个关键挑战。在这里,我们报告了四种临床口服 PROTAC 在小鼠、大鼠和犬中的药代动力学特性,并与内部获得的数据集进行了比较。我们使用 NMR 来确定三维分子构象和在溶液中自由的结构预组织,并且我们引入了新的实验描述符,溶剂暴露的氢键供体(eHBD)和受体(eHBA)。我们为非极性环境中的口服 PROTAC 确定了 eHBD≤2 的上限,并显示出对其他性质(eHBA、极性、亲脂性和分子量)的更大耐受性,而不是对符合规则 5 的口服药物的耐受性。在一组结构相关的 PROTAC 中,我们表明,eHBD>2 的例子的口服生物利用度远低于 eHBD≤2 的例子。我们将我们的发现总结为一个实验性的“口服 PROTAC 规则”,以帮助药物化学家在这个具有挑战性的领域实现口服生物利用度。